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Abstract: 
 Rate-limiting dissociation of the tetrameric protein transthyretin (TTR), followed by 
monomer misfolding and misassembly, appears to cause degenerative diseases in humans known 
as the transthyretin amyloidoses, based on human genetic, biochemical and pharmacologic 
evidence.  Small molecules that bind to the generally unoccupied thyroxine binding pockets in 
the native TTR tetramer kinetically stabilize the tetramer, slowing subunit dissociation 
proportional to the extent that the molecules stabilize the native state over the dissociative 
transition state—thereby inhibiting amyloidogenesis.  Herein, we use previously reported 
structure-activity relationship data to develop two semi-quantitative algorithms for identifying 
the structures of potent and selective transthyretin kinetic stabilizers / amyloidogenesis 
inhibitors.  The viability of these prediction algorithms, in particular the more robust in silico 
docking model, is perhaps best validated by the clinical success of tafamidis, the first-in-class 
drug approved in Europe, Japan, South America, and elsewhere for treating transthyretin 
aggregation-associated familial amyloid polyneuropathy. Tafamidis is also being evaluated in a 
fully-enrolled placebo-controlled clinical trial for its efficacy against TTR cardiomyopathy. 
These prediction algorithms will be useful for identifying second generation TTR kinetic 
stabilizers, should these be needed to ameliorate the central nervous system or ophthalmologic 
pathology caused by TTR aggregation in organs not accessed by oral tafamidis administration.   
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Human genetic, biochemical and pharmacologic evidence implicates rate-limiting 
transthyretin (TTR) tetramer dissociation, followed by rapid monomer misfolding and 
misassembly, as the cause of several degenerative diseases exhibiting overlapping phenotypes, 
collectively referred to as the transthyretin amyloidoses.1-16  The amyloidogenic TTR monomer 
misassembles into a variety of aggregate structures during amyloidogenesis, including cross-β-
sheet amyloid fibrils, for which these diseases are named.17-19  Amyloidogenesis of wild-type 
(WT) TTR or aggregation of certain mutants along with WT-TTR in heterozygotes leads to 
cardiomyopathies, affecting up to 500,000 individuals (disorders historically called senile 
systemic amyloidosis (SSA) and familial amyloid cardiomyopathy (FAC), respectively).14, 20  
Amyloidogenesis of distinct TTR mutants along with WT-TTR in heterozygotes results in a 
primary autonomic and peripheral neuropathy, often called familial amyloid polyneuropathy 
(FAP). The latter disease has historically been treated by liver transplant-mediated gene therapy, 
wherein the mutant-TTR / WT-TTR liver (which secretes destabilized TTR heterotetramers) is 
replaced by a WT-TTR / WT-TTR liver (which secretes a more stable WT-TTR homotetramer). 
Interestingly, slowing the course of peripheral disease progression by liver transplantation has 
led to the appearance of TTR aggregation in the central nervous system (CNS) and eyes, which 
manifests as a consequence of treatment-associated lifespan extension.21-26  
Another strategy to prevent TTR amyloidogenesis is to fashion small molecules that bind 
selectively in human blood to one or both of the thyroxine (T4) binding sites comprising the 
tetramer made up of WT or mutant and WT subunits. Selective binding to the native tetrameric 
ground state of TTR over the dissociative transition state raises the kinetic barrier for subunit 
dissociation, substantially slowing TTR aggregation. The extent of kinetic stabilization of 
tetrameric TTR determines the extent to which amyloidogenesis is inhibited.27-31 A placebo-
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controlled clinical trial in V30M FAP patients (a prominent mutation causing tetramer 
destabilization), along with a 12-month extension study, demonstrates the efficacy of this 
strategy in slowing the progression of autonomic and peripheral neuropathy.32, 33 
Our studies carried out over the last two decades to develop small molecule TTR 
amyloidogenesis inhibitors have revealed that optimal TTR kinetic stabilizers are typically 
composed of two aryl rings joined by linkers of variable chemical composition.28, 29, 34-55  Figure
S1 and Table S1 in the Supporting Information contain compilations of the structures and 
experimental results for the majority of the inhibitors procured or synthesized by the Kelly 
laboratory during this period.  Binding of these small molecules to one or both of the generally 
unoccupied, funnel-shaped, T4 binding pockets strengthens the weaker dimer-dimer interface of 
TTR by non-covalently bridging adjacent monomeric subunits through specific hydrophobic and 
electrostatic interactions, as exemplified in the TTR•(201)2 crystal structure (Figure 1).  To 
gauge the efficacy of candidate molecules to bind to the T4 pockets and kinetically stabilize the 
TTR tetramer from dissociating and aggregating in complex biological environments, we rely on 
two primary assays: 1) an in vitro acid-mediated TTR aggregation assay carried out with 
recombinant TTR in buffer; and 2) an ex vivo TTR immunoprecipitation / HPLC assay to 
quantify the stoichiometry of a candidate kinetic stabilizer bound to TTR in blood plasma.  These 
two assays are briefly explained below, with complete experimental details presented in the 
Supporting Information).56, 57 
Figure 1:  X-ray structure of the TTR•(201)2 complex (PDB ID 5TZL) highlights the 
interactions known to be important for tight binding to TTR.  Compound 201 is bound in its 
equivalent symmetry-related binding modes (grey and green, respectively), which results from 
ligand binding along the crystallographic 2-fold axis.  The omit FO-FC density (contoured at +/- 
3.5) for 201 is shown in Figure S3 of the Supporting Information.   The binding pocket is 
characterized by a smaller inner cavity and a larger outer cavity, throughout which are 
distributed three pairs of symmetric hydrophobic depressions, referred to as the halogen binding 
pockets (HBPs).  The iodine and chlorine atoms of 201 reside within HBPs 1 and 3.  Primed 
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amino acids or HBPs refer to symmetry-related monomers of TTR comprising each T4 binding 
pocket.  The phenolate of 201 makes charged interactions with the Lys 15 and 15' residues in the 
outer cavity; however, it is known that other kinetic stabilizers composed of phenols exhibiting a 
higher pKa preferentially bind in the opposite orientation so that the phenols can hydrogen bond 
with the Ser-117 and 117' residues in the inner binding cavity (details of this phenomenon have 
been previously reported).46-50   
 
 
The acid-mediated TTR aggregation assay (pH 4.4; 100 mM acetate buffer) probes the 
ability of a candidate small molecule kinetic stabilizer to bind tetrameric TTR in vitro and 
prevent amyloidogenesis under denaturing conditions that destabilize the tetramer, and largely 
convert the dissociated TTR monomers to aggregates within 3 days in the absence of a kinetic 
stabilizer.  The best inhibitors prevent >90% of TTR aggregation over a 72 h time course when 
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incubated at a concentration twice that of tetrameric TTR (i.e., 7.2 µM candidate inhibitor versus 
3.6 µM tetrameric TTR).  We have traditionally presented results as % fibril formation (% FF), 
with complete arrest of TTR aggregation (i.e., 100% inhibition) corresponding to 0% FF.   
Since plasma TTR is the form that undergoes amyloidogenesis and causes degenerative 
phenotypes in the periphery, a kinetic stabilizer candidate must bind selectively to TTR over all 
the other proteins in blood plasma to be efficacious.  The ex vivo TTR immunoprecipitation / 
HPLC quantification assay probes the ability of candidate kinetic stabilizers to bind selectively 
to TTR over the 4000+ other proteins that are present in human blood plasma. Selectively 
binding to TTR over albumin, which is the primary T4 transport protein in the blood, can be 
particularly challenging: TTR represents <0.5% by mass of the total plasma proteome, whereas 
albumin comprises ~57%.58 Potent TTR kinetic stabilizers can display average plasma TTR 
binding stoichiometry values, also referred to as the Plasma Binding Selectivity (PS) values, 
between zero (i.e., the candidate small molecule binds predominantly to plasma proteins other 
than TTR) and the theoretical maximum of two (i.e., the candidate kinetic stabilizer binds very 
selectively to TTR in blood plasma and exhibits a slow dissociation rate), owing to the presence 
of the two T4 binding sites per TTR tetramer. A PS value of 0 renders a compound useless as a 
TTR amyloidogenesis inhibitor in vivo, whereas a PS value of 1 or higher is acceptable as our 
previous studies show that only one inhibitor bound per TTR tetramer is necessary to kinetically 
stabilize the WT-TTR tetramer against amyloidogenesis.29 In addition to mitigating off-target 
toxicity during the envisioned life-long use of a kinetic stabilizer to ameliorate a TTR amyloid 
disease, achieving a high PS value may also allow administration of lower amounts of drug while 
still maintaining efficacy. 
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Our early studies looked at the potential of repurposing approved non-steroidal anti-
inflammatory drugs (NSAIDs) to serve as TTR kinetic stabilizers, and thus inhibit the process of 
TTR amyloidogenesis.38-41 During these investigations, we discovered that diflunisal (compound 
389) is a viable TTR kinetic stabilizer and inhibitor of TTR aggregation in vitro.  Diflunisal is an 
effective TTR kinetic stabilizer in humans because it can achieve extremely high plasma 
concentrations, which makes up for its modest binding constant and mediocre binding 
selectivity.  Since diflunisal is already an approved drug in many countries around the world, this 
discovery was instrumental in setting up an international academic clinical trial to test the 
efficacy of TTR kinetic stabilizers as a strategy to treat FAP.  While the clinical trial of tafamidis 
to ameliorate V30M FAP (see below) was completed first, the diflunisal FAP trial (all mutations) 
ultimately showed that treatment with diflunisal reduces the rate of progression of neurological 
impairment and preserves the quality of life in polyneuropathy patients.59 However, the long 
term therapeutic use of diflunisal for the treatment of the transthyretin amyloidoses is limited by 
the fact that, as an NSAID, it can trigger gastrointestinal bleeds and impair renal flow,59-64 which 
is already diminished in cardiomyopathy patients. Hence, diflunisal is contraindicated for TTR 
cardiomyopathy patients.  Thus, we focused on developing lead TTR kinetic stabilizers / 
amyloidogenesis inhibitors that did not inhibit cyclooxygenase activity.   
Early on in our TTR kinetic stabilizer development program, it became clear that some of 
the most potent TTR kinetic stabilizers under evaluation also exhibited binding to the thyroid 
hormone receptors, which would likely produce undesirable metabolism and heart rate side-
effects in the envisioned long-term use of TTR amyloidogenesis inhibitors. Thus, we also sought 
TTR kinetic stabilizers that were neither thyroid agonists nor antagonists. 
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Through extensive medicinal chemistry optimization efforts and counter-screens to avoid 
NSAID or thyroid hormone receptor activity, one TTR kinetic stabilizer emerged as a lead drug 
candidate, tafamidis (compound 250), which has since been approved by regulatory agencies in 
>30 countries for treating FAP, causatively linked to over 100 TTR mutations.  The 18-month-
long clinical trial, the 12-month extension study, and observations of more than 1000 patients, 
some for longer than 8 years, indicate a very favorable safety profile and clearly demonstrate the 
therapeutic efficacy of tafamidis at delaying neurologic impairment and preserving nutritional 
status in polyneuropathy patients, while enhancing quality of life and likely lifespan.32, 33, 64, 65 
Unfortunately, a drawback to current therapies is that a subset of liver transplant patients with 
FAP, and some tafamidis-treated patients, present with continued ocular and CNS deposition of 
TTR aggregates (tafamidis does not enter the eye or the brain upon oral administration). It seems 
that the majority of FAP patients treated by liver transplant-mediated gene therapy develop CNS 
amyloid pathology after more than a decade of treatment. Thus, it may be necessary to develop a 
second generation, tafamidis-like molecule that enters the eye and the brain while still 
maintaining TTR kinetic stabilization in the periphery.  
To increase the success of developing second generation transthyretin kinetic stabilizers / 
amyloidosis inhibitors, in the present study, we have developed two semi-quantitative models to 
predict the structures of potent TTR kinetic stabilizers / amyloidogenesis inhibitors that bind 
with high selectivity to TTR in the blood, and that exhibit minimal off-target effects, such as 
binding to the thyroid hormone receptor or the cyclooxygenase enzymes.  The development of 
these two prediction models will allow us to more effectively focus future research efforts on 
optimizing the CNS and ocular permeability of TTR kinetic stabilizers, since we can be 
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confident that, even before any synthesis commences, proposed lead candidates will have a high 
probability of selectively targeting transthyretin. 
Figure 2.  Summary of the structure-activity relationships (data derived) from a trio of previous 
libraries designed to screen the three substructures of a typical small molecule TTR amyloidosis 
inhibitor (i.e., Aryl-X, Linker-Y, and Aryl-Z).46-48  Substructures are quantitatively ranked 
according to the average experimental efficacy scores (EES) as determined using Equation 1, 
which evaluates the ability of a substructure to afford potent aggregation inhibitors in vitro that 
bind selectively to TTR in human blood plasma ex vivo.   
 
 
 
Previously, we synthesized and evaluated three libraries of TTR kinetic stabilizer 
candidates in an effort to optimize the three substructures of a typical TTR amyloidogenesis 
inhibitor – the two aromatic rings and the linker joining them (Figure S1, compounds 1-134).46-
48
  The structure-activity relationship (SAR) data from these three mini-libraries (detailed in the 
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previous studies and summarized in Figure 2)46-48 were envisioned to contain the information 
enabling one to predict the potency and selectivity of a larger combinatorial library of 
“theoretical” TTR amyloidogenesis inhibitors.  For the envisioned predictive algorithm, 
Equation 1 was developed, incorporating an equal weighting of inhibitor potency (based on % 
FF) and plasma TTR binding selectivity (PS), to semi-quantitatively rank compounds by what 
we call an Experimental Efficacy Score (EES).   
Equation 1 
 =
100%−%

 × 1 + 
300%
 
 
EESs range from 0 (least potent and selective inhibitors) to a maximum of 1, which corresponds 
to a compound displaying maximal amyloidogenesis inhibition (0% FF) and a maximum binding 
selectivity value of 2 (i.e., both T4 binding sites are occupied by a kinetic stabilizer in blood 
plasma). The EES values for the Aryl-X, Aryl-Z, and Linker-Y substructures can then be used to 
calculate what we refer to as a Predicted Efficacy Score (PES) for a theoretical candidate 
molecule (Equation 2).  
Equation 2 
 =  +  +  +  +  
In this algorithm, the Aryl-X substructure EESs have been further subdivided into Xs and Xp 
EESs (values are presented in Figure 2), to differentiate contributions from substituents and the 
substitution patterns, respectively. The Aryl-Z substructure EESs have been similarly subdivided 
into Zs and Zp EESs (values are presented in Figure 2).  A detailed description of how to 
calculate PES values for a given molecule is presented in the Supporting Information (page 16). 
Briefly, to calculate a molecule’s PES, the EES values for the Xs, Xp, Y, Zs, and Zp substructures 
that characterize the molecule (as defined in Figure 2) are simply added together (Equation 2).  
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With EESs for the Xs, Xp, Y, Zs, and Zp parameters (9, 6, 10, 10, and 8 substructures, 
respectively) derived from the three small libraries consisting of 134 molecules,46-48 we are able 
to calculate PESs for 43,200 theoretical TTR kinetic stabilizer small molecules, although some 
structural overlap occurs owing to molecular symmetry, which reduces the total number of 
distinct chemical entities. In theory, PES values can range from 0 (least potent and selective 
inhibitors) to a maximum of 5 (most potent and selective inhibitors); however, the current 
practical range spans between ~0.5 - 3.0 as EESs never reach the limits of 0 or 1 for any of the 
individual molecular substructures.   
Next, we scrutinized whether the PES algorithm could enhance our ability to chemically 
synthesize a high proportion of potent and selective TTR amyloidogenesis inhibitors.  As our test 
case, we employed a library of stilbene and dihydrostilbene compounds reported previously49 
with calculated PESs in the 1.9-2.9 range (i.e., at the higher end of the practical PES range).  In 
this test library, 93% of the stilbenes (52/56, compounds 135-174) and 100% of the 
dihydrostilbenes (34/34, compounds 175-199) displayed EESs greater than 0.667, an important 
cutoff that represents a scenario of 0% FF and a binding stoichiometry of ≥1 molecule per TTR 
tetramer. A complete tabulation of % FF, PS, EES, and PES values for the stilbene and 
dihydrostilbene compounds can be found in Table S1 in the Supporting Information.   
When EESs are plotted vs. PESs for those compounds containing substructures 
encompassed within this prediction model (i.e., substructures presented in Figure 2) – from the 
four aforementioned small molecule libraries (1-199)46-49 along with 19 new compounds reported 
here (200-218) and previously evaluated compounds (243-314)28, 29, 35-41, 43-45, 51-55 – it becomes 
evident that enrichment of compounds with EESs above the 0.667 cutoff occurs for compounds 
with PESs >1.8 (Figure 3; shaded area). Solid black data points (see rightmost Y-axis in Figure 3) 
  
12 
represent the percentage of compounds exceeding the EES = 0.667 cutoff (PES data plotted in 
increments of 0.2).  Thus, focusing synthetic efforts on compounds with PESs ≥1.8 should 
enhance the development of a higher proportion of potent and selective TTR amyloidogenesis 
inhibitors.  While this PES approach appears to have value in terms of directing synthetic efforts 
towards developing potent TTR kinetic stabilizers that display high binding selectivity in blood 
plasma, and presumably in cerebrospinal fluid (to be determined), experimental evidence 
suggests that these types of predictions may not directly translate into developing the most 
promising clinical candidates, as exemplified by the situation for compound 201. 
Figure 3.  Examination of the correlation between Predicted Efficacy Scores (PES) of kinetic 
stabilizers and their Experimental Efficacy Scores (EES).  EES and PES values for individual 
compounds were calculated using Equations 1 and 2, respectively.  The dashed line at EES = 
0.667 represents a scenario where an inhibitor binds with a stoichiometry of 1 molecule per TTR 
tetramer, which has been shown sufficient to completely inhibit TTR aggregation (i.e., 0% fibril 
formation).29  Solid black data points represent the percentage of compounds within the 0.2 PES 
bins that exceed the EES=0.667 cutoff.  The area shaded grey represents the PES region where 
significant enrichment of molecules above this cutoff occurs: that is, where the greatest 
proportion of highly desirable, potent and selective TTR aggregation inhibitors are predicted 
(PES > 1.8).  Please refer to Table S1 in the Supporting Information for a complete tabulation of 
all values.   
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Compound 201 (PES = 2.682) was one of the first candidates to undergo further 
evaluation as a result of this substructure optimization study and embodies the pinnacle of TTR 
aggregation inhibition and blood plasma TTR binding selectivity (EES = 0.97).  Examination of 
the TTR•(201)2 co-crystal structure (Figure 1) reveals that 201 complements the T4 binding site 
nearly perfectly, justifying its binding affinity and plasma selectivity.  However, it fails as a 
promising drug candidate because it binds significantly to the thyroid hormone (TH) nuclear 
receptor (relative TH receptor binding = 0.93 – i.e., it displaces 93% of radiolabled T3 [the 
endogenous thyroid hormone] from the receptor at a concentration of 10 µM), which is an 
undesirable characteristic for a molecule that would be used daily for the remainder of a patient’s 
life.  Forewarning of this off-target binding was not possible using the PES approach, since most 
of the compounds in the three libraries from which the Xs, Xp, Y, Zs, and Zp parameters were 
derived lacked any appreciable TH receptor binding.46-48  Of the 70 highly potent and selective 
TTR kinetic stabilizers evaluated for TH receptor binding efficacy in the aforementioned 3 
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libraries, only 3 compounds displaced T3 by >20% (compounds 46, 110, and 111, with relative 
TH receptor activities of 0.28, 0.21, and 0.28, respectively).   
Prior to the creation of the fourth library, the stilbene and dihydrostilbene library,49 
emerging evidence from a panel of compounds designed to validate this lead candidate 
predictive algorithm (compounds 200-218 and others that were later incorporated into the 
stilbene and dihydrostilbene scaffold) suggested that molecules at the high end of the PES range 
stood a greater chance of binding to the TH nuclear receptor.  However, it appeared that 
investigating compounds with sub-optimal PES values could alleviate this issue.  To probe what 
appeared to be the transition zone from low-to-high TH receptor binding, we investigated the 
stilbene and dihydrostilbene compound series.49  Of the 21 stilbenes tested, 15 (68%) display 
relative TH receptor binding activities exceeding the 0.2 threshold; however, only 17% of the 
dihydrostilbene compounds tested (2/12) exceeded the 0.2 threshold.  A correlation is evident 
from plotting the accumulated relative TH receptor binding results as a function of PES for all 
compounds evaluated to date (Figure 4). TH receptor binding increases significantly at PES 
values >2.5.  As evidenced by the stilbene/dihydrostilbene results (∆PES~0.115), decreasing the 
PES by a small amount can have a profound effect on the likelihood that a candidate TTR kinetic 
stabilizer will bind the thyroid hormone receptor.   
Figure 4.  Examination of the correlation between kinetic stabilizer Predicted Efficacy Scores 
(PES) of the candidate kinetic stabilizers and their Relative Thyroid Hormone (TH) receptor 
binding.  A cutoff for undesirable TH receptor binding has been selected at 0.2, represented by 
the dashed line.  Solid black data points represent the percentage of compounds within the 0.2 
PES bins that are below this threshold.  The area shaded grey represents the PES region where 
significant enrichment of molecules below this cutoff occurs: that is, where the greatest 
proportion of highly desirable molecules that do not bind to the TH receptor are predicted (PES < 
2.5).  Please refer to Table S1 in the Supporting Information for a complete tabulation of all 
values.   
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Given that the most promising clinical candidates are not necessarily those with the 
highest Predicted Efficacy Scores, we reassessed the scoring algorithm to incorporate a “negative 
design” component, i.e., to select against compounds exhibiting TH receptor binding capacity.  
Toward this end, the Experimental Efficacy Scoring function of Equation 1 was modified to 
integrate relative TH receptor binding results and compute what we refer to as a Thyroid 
Hormone Receptor Experimental Efficacy Score, or THREE Score (Equation 3).   
Equation 3 
	 =
100%	 − 	%

	×	 1 + 
300%
− .  
 
Consistent with data in Figures 3 and 4, plotting THREE Scores as a function of PES (Figure 5) 
demonstrates an enrichment of compounds that exceed the 0.667 threshold within the 1.8-2.5 
PES range (shaded area), with a maximum occurring at a PES of ~2.2 (refer to Table S1 in the 
Supporting Information for a tabulation of all THREE Score results).   
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Figure 5.  Examination of the correlation between the Predicted Efficacy Scores (PES) of the 
candidate kinetic stabilizers and their Thyroid Hormone Receptor Experimental Efficacy Scores 
(THREE Scores).  THREE Score values for individual compounds were calculated using 
Equation 3.  The cutoff line at 0.667 represents 1 inhibitor bound per TTR tetramer as described 
in Figure 3.  Solid black data points represent the percentage of compounds within the 0.2 PES 
bins that exceed the 0.667 cutoff.  As in Figure 3, the highest proportion of potent and selective 
TTR aggregation inhibitors occurs at PES values >1.8; however, at PES values above 2.5, 
binding to the TH receptor decreases the THREE score values significantly.  Thus, the most 
promising potent and selective TTR amyloidogenesis inhibitors that display minimal binding to 
the TH receptor are predicted in the PES=1.8-2.5 range (i.e., the area shaded grey).  Please refer 
to Table S1 in the Supporting Information for a complete tabulation of all values.   
 
While these Predicted Efficacy Scores are useful for identifying candidate TTR kinetic 
stabilizers, this semi-quantitative optimization algorithm has several deficiencies that limit its 
effectiveness.  For one, this algorithm is limited to predicting the efficacies of compounds 
encompassed within the scope of the scaffold substructures included in the Aryl-X, Aryl-Z, and 
Linker-Y optimization studies (i.e., limited to the substructures presented in Figure 2).46-48  
Furthermore, PES calculations can be ambiguous owing to molecular symmetry that does not 
permit unambiguous assignment of Aryl-X and Aryl-Z rings; thus, scoring in both directions is 
possible, which may not give the same PES values (this issue is described in more detail with 
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compound 88 in Figure S2B of the Supporting Information). Scaffolds such as the benzoxazoles, 
featuring substituent patterns that do not fall within the general classification of ortho, meta, and 
para, also complicate PES calculations.  PES comparisons are further complicated by the 
differences in linker lengths and angles between the aryl rings (e.g., biphenyls vs. a urea linker 
vs. a biphenyl ether linker, etc.), distinctions in substituent orientation on different scaffolds, and 
the orientation differences of the candidate kinetic stabilizers within the TTR T4 binding sites, 
which this algorithm assumes are equivalent.  We also note that carboxylates were not highly 
represented in the three mini-libraries that serve as the basis for this strategy.46-48  In prior SAR 
studies, carboxylate-bearing aryls strongly favor binding to the outer cavity of the T4 binding 
site.  However, in one of the mini-libraries,48 a 3,5-Br2-4-OH aryl-X group was employed that 
preferred binding in the outer cavity; thus, the carboxylates on the aryl-Z ring were unfavorably 
positioned into the inner binding cavity, leading to their assignment of low Zs scores.  We know 
that for many inhibitors, carboxylates are not as much of a liability as this scoring algorithm 
would suggest.  This deficiency is highlighted by the results of tafamidis (compound 250), 
which, while proving to be an excellent drug for treating FAP, would not have been predicted as 
a lead candidate using this algorithm: PES = 1.558, EES = 0.597, and THREE Score = 0.597.  
Thus, if we had evaluated a larger data set, carboxylate substituents might have been suggested 
as more favorable and tafamidis would likely have fallen within the 1.8-2.5 PES range for 
optimal candidates to select for further pre-clinical and clinical evaluation.   
To counter the deficiencies inherent in the PES algorithm described above, we evaluated 
the viability of an in silico docking model for predicting the efficacy of TTR kinetic stabilizers.  
In this approach, we obtained docking energies for all of the compounds listed in Figure S1 and 
Table S1 by docking them to the unliganded TTR derived from the TTR•(201)2 complex 
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structure using AutoDock 4.66-68  We used the apo-TTR from the TTR•(201)2 crystal structure 
because 201 exhibits one of the highest experimental efficacy scores that we have ever observed 
(EES = 0.97) – the idea being that TTR adopts this structure because of complementarity to an 
ideal kinetic stabilizer from a TTR binding perspective.  The detailed protocol employed for 
compound docking to TTR is outlined in the Supporting Information.  Briefly, compound 
structures were created using ChemDraw, then their conformational energy was minimized using 
Accelrys Discovery Studio 4.  The compound docking files, the receptor docking files, and 
docking parameter files were prepared using AutoDockTools 1.5.6.  The receptor grid maps were 
established using the AutoGrid4 program, with a grid box large enough to encompass both of the 
thyroxine binding sites so that the molecules could dock to either site in a single simulation.  
Compounds were then docked in the receptor employing triplicate simulations and the docking 
conformations and energies were evaluated in AutoDockTools.  If the docked conformations 
were considered reasonable (i.e., bound in conformations that we would expect based on our 
prior experience observing numerous TTR•(Inhibitor)2 co-crystal structures, but in general with 
RMSDs < 8Å – see validation discussion below), the docking energies were recorded in Table 
S1 (representing the average of the three docking energies).  In 92.2% of the dockings, the 
lowest energy conformations were considered reasonable and bound in conformations we would 
expect.  For the remaining 7.8% of the dockings, the lowest energy conformations had the 
molecules either not positioned within the binding site or in conformations that we have not 
previously observed; however, in all cases, we were able to observe reasonable binding 
conformations for higher energy docked structures.  Therefore, we recorded these higher energy 
docking conformations in Table S1, rather than the lowest docking energies for the 
conformations that were deemed unreasonable. 
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Figure 6. The lowest energy docked conformation of inhibitor 201 calculated using Autodock 4 
superimposes nearly identically with the TTR•(201)2 co-crystal structure (RMSD = 0.44 Å; 
calculated using the Accelrys Discovery Studio 4 crystallographic visualization program). 
 
 
 
We validated that the docking of inhibitors provided reasonable binding conformations 
by comparing the docked conformations of 30 inhibitors with their established TTR•(kinetic 
stabilizer)2 co-crystal structures.  Of the 30 docked compounds, 23 of them (77%) had RMSD 
values that differed by <2.5 Å compared to their X-ray co-crystal structures (refer to Figure S4 
in the Supporting Information).  Compound 201 docked with an RMSD of 0.44 Å compared to 
the established TTR•(201)2 crystal structure (Figure 6).  The remaining compounds had higher 
RMSD values (but still < 8Å) owing to binding in the opposite orientation in the T4 binding site 
relative to that observed in the crystal structures (i.e., binding backwards in the TTR thyroid 
hormone binding pocket).  While this indicates a failure of AutoDock to re-capitulate the 
conformations observed in these seven TTR•(Inhibitor)2 co-crystal structures, we still considered 
these docking conformations reasonable as we have often seen compounds binding in 
orientations opposite to what we might have predicted based on historical SAR.  Furthermore, 
we have also observed compounds binding in mixed forward and reversed orientations in the 
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same structures, indicating the energetic differences between the two orientations can be small, 
with both likely sampled in the solution state.  Based on these results, we had high confidence 
that AutoDock 4 was effective at predicting reasonable binding conformations and that the 
docking model would provide robust and physiologically relevant binding rankings. 
The initial docking scores for each of the compounds (i.e., raw docking scores as 
computed by AutoDock 4, presented in Table S1) were plotted against in vitro biochemical 
results to evaluate potential correlations (Figure S5, left panels, in the Supporting Information).  
Autodock 4 generates calculated docking scores as binding energies (in kcal/mol units); thus, 
lower docking scores (i.e., more negative) correspond to tighter binding kinetic stabilizers.  Upon 
closer examination of the correlations, it appears that the scoring algorithm that AutoDock 4 uses 
to calculate docking energies was over-estimating the contributions that –CO2H and –NO2 
substituents made to the docking energies (at least in this context of binding to TTR).  Thus, we 
decided to assign “correction factors” to the AutoDock 4 calculated docking energies for 
compounds bearing –CO2H and –NO2 substituents, which came to be +1.03 and +2.37 kcal/mol 
for the carboxyl and nitro substituents, respectively.  Since we are perturbing these docking 
energies using correction factors for the –CO2H and –NO2 substituents, we feel that representing 
the corrected values as energies is not entirely valid, and thus we represent the results as docking 
“scores” omitting the units (kcal/mol).  A detailed description of how we determined these 
“correction factors” and how they are used to compute corrected docking scores is presented in 
the Supporting Information.   
As with the Predicted Efficacy Scores, we compared the corrected in silico docking 
scores for all the inhibitors against the various biochemical results and scoring functions (Figure 
7).  As shown in Figure 7A, the most potent TTR kinetic stabilizers (aggregation inhibitors) in 
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vitro are those with corrected docking scores lower than -7.  The corrected docking scores also 
correlated with the candidate kinetic stabilizer plasma binding stoichiometries (Figure 7B) and, 
consequently, the Experimental Efficacy Scores (Figure 7C).  There was also a trend noted that 
the lower the corrected docking score, the greater the chance a molecule had for binding to the 
thyroid hormone receptors (Figure 7D).  From these correlations, it appears that the “sweet spot” 
for predicting the most promising lead candidate kinetic stabilizers is associated with a docking 
score ranging from -7.5 to -9.0 (Figure 7E).  Perhaps not surprisingly, the corrected docking 
score for tafamidis is -7.83, which falls within this range.  Thus, this in silico optimization 
algorithm further supports that tafamidis is an excellent transthyretin kinetic stabilizer, a 
prediction borne out by its clinical efficacy.   
While we would like to include a “negative design” component to this in silico algorithm 
that incorporates scores from docking to the thyroid hormone receptors and cyclooxygenases, the 
scale of this endeavor renders it beyond the scope of what can be included in the initial paper. 
Ideally, we would like more than ten X-ray crystal structures of candidate TTR kinetic stabilizers 
bound to the thyroid hormone receptors and cyclooxygenases, and these data are lacking. While 
other thyroid hormone receptor and cyclooxygenase crystal structures are available (i.e. those 
without TTR kinetic stabilizer ligands), we fear that docking results using these structures may 
not prove reliable.  Future studies linking thyroid hormone receptors and cyclooxygenase co-
crystal structures and docking experiments with TTR kinetic stabilizer candidates are warranted 
to potentially add this negative design component. 
Figure 7.  Examination of the correlations between corrected in silico docking scores of 
candidate kinetic stabilizers and their in vitro % inhibition of TTR aggregation (A); ex vivo 
plasma TTR binding stoichiometry (B); Experimental Efficacy Scores (C); Relative Thyroid 
Hormone receptor binding (D); and Thyroid Hormone Receptor Experimental Efficacy Scores 
(E).  Please refer to Table S1 in the Supporting Information for a complete tabulation of all 
values.  In panels A, B, C, and E, solid black data points represent the percentage of compounds 
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within the 0.5 docking score bins that are above the respective thresholds (90% for inhibition of 
TTR aggregation for panel A; 1 molecule bound per TTR tetramer for panel B; and 0.667 for C 
and E, representing 100% inhibition of TTR aggregation and 1 molecule bound per tetramer).  In 
panel D, solid black data points represent the percentage of compounds within the 0.5 docking 
score bins that are below the 0.2 threshold for undesirable thyroid hormone receptor binding.  
Areas shaded grey represent the docking score regions where significant enrichment of 
molecules above the respective cutoffs occur (or below with respect to thyroid hormone receptor 
binding).  In panel E, the greatest proportion of highly desirable, potent, and selective TTR 
aggregation inhibitors are predicted within the -7.5 to -9.0 docking score region. 
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In conclusion, we have developed two semi-quantitative models for predicting the 
optimal structures of potent and selective transthyretin kinetic stabilizers / amyloidogenesis 
inhibitors.  While in our initial Predicted Efficacy Scoring model, tafamidis fell slightly out of 
the range for predicting the best lead candidates to pursue for further pre-clinical development, it 
did fall within the optimized inhibitor zone using our in silico docking model, which we believe 
is the more robust of the two predictive algorithms.  Thus, not only is tafamidis predicted to be a 
bona fide lead candidate, but the clinical success of tafamidis also supports this algorithm as a 
useful tool for predicting promising lead transthyretin amyloidogenesis inhibitors for treating the 
transthyretin amyloidoses.  These prediction algorithms should be useful for identifying second 
generation TTR kinetic stabilizers, should these be needed to ameliorate CNS or ophthalmologic 
challenges caused by TTR aggregation from TTR synthesized by the choroid plexus and the 
retinal pigment epithelial cells, respectively. 
 
Supporting Information  
Supporting information associated with this article can be found in the online version, which 
includes a compilation of compounds developed in the Kelly lab for which % fibril formation 
and Plasma Selectivity values are available; tabulated values of experimental results for these 
compounds; guidelines for calculating compound Predicted Efficacy Scores (PESs); synthesis 
and evaluation procedures for new molecules presented in this manuscript; X-ray crystallography 
procedures and structure data for the TTR•(201)2 X-ray co-crystal structure; procedures for 
docking of molecules to the unliganded TTR from the TTR•(201)2 crystal structure using 
AutoDock 4; comparison of the lowest energy docked conformations of molecules with their 
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TTR•(molecule)2 co-crystal structures; and a description of the procedure for determining the –
CO2H and –NO2 substituent correction factors and calculation of corrected docking scores. 
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